The objective of the study is to construct a noninvasive approach 68Ga-TTP PET/CT to detect the TROP2 expression of tumor lesions in patients with breast tumors and evaluate the efficacy of ADC drug therapy.
Age 18-75 years old, male or female, ECOG score 0 or 1 points (see the table in Annex 2 for the score table);
Blood routine and liver and kidney function meet the following criteria: Blood routine: WBC ≥ 4.0×109 L or neutrophil ≥1.5×109 /L, PLT ≥ 100×109/L, Hb≥ 90 g/L; PT or APTT ≤ 1.5 ULN; Liver and kidney function: T-Bil ≤ 1.5×ULT(upper limit of normal), ALT and AST≤ 2.5 ULN or ≤ 5×ULT(subjects with liver metastasis), ALP ≤ 2.5 ULN(ALP ≤ 4.5 ULN if there is bone metastasis or liver metastasis); BUN ≤ 1.5×ULT, SCr ≤ 1.5×ULT;
Patients with confirmed or suspected breast cancer;
Expected survival ≥12 weeks;
Severe abnormal liver and kidney function;
Pregnant, pregnant and lactating women;
Can not lie flat for half an hour;
Unable to obtain informed consent;
Peking University Cancer Hospital & Institute
Lead sponsor
Yunnan Cancer Hospital
Collaborator